Introduction
============

*Escherichia coli* is the leading bacterial pathogens responsible for intestinal and extraintestinal infections, including urinary tract infections, bacteremia, and meningitis ([@B23]). Certain strains of *E. coli* have been shown to carry certain genes coding for enzymes that hydrolyze a wide range of beta-lactams and are referred to as extended-spectrum beta-lactamase producing *E. coli* (ESBL-EC). In recent years, the dissemination of ESBL-EC has become a serious health problem worldwide including Turkey ([@B34]; [@B38]; [@B44]; [@B21]). ESBL producing pathogens are known to be resistant not only first, second, and third generation cephalosporins and monobactams, but also to several other classes of antibiotics. As a result, infections that are difficult to treat occur, and occasionally the use of "antibiotics of the last resort" such as carbapenems, colistin is inevitable ([@B6]). However, unfortunately, emergence of resistance against these drugs of last resort is also observed around the world ([@B40]; [@B19]). The upcoming threat of increase in the prevalence of untreatable infections has motivated the quest for alternatives of antibiotic therapy.

Bacteriophages (phages) are natural parasites of bacteria and they have been considered as effective agents for the treatment of bacterial infections since 1920s ([@B42]; [@B12]). The reason phages have been used as antimicrobial agents in that they can recognize, bind onto, and reproduce within a bacterial host, resulting in rapid cell lysis. However, poor understanding of phage biology and inconsistent outcomes experienced in early trials resulted in the phage therapy never being adopted universally ([@B42]; [@B26]). The advancement and consequently widespread use of antibiotics left phage therapy remaining as a common practice confined in the former Iron Curtain Countries where it has been successfully applied for around 90 years. Currently, although antibiotic therapy is successful in the treatment of majority of infections, frontline therapies are not effective in noticeable amount exceptions ([@B18]; [@B17]; [@B24]) which is the underlying reason for the revitalization of phage therapy in bacterial infections around the world ([@B31]). Thus, adopting this renewed approach we designed this preliminary study on ESBL-EC since it is a significant infection control and treatment challenge in the world.

This study aimed to examine the *in vitro* activity of Georgian bacteriophage cocktails which are used as part of standard clinical practice in the Republic of Georgia on a well-characterized ESBL-EC isolated from Turkish patients' blood and urine. As this is a first step to the potential clinical trials to be designed for the countries that have reached a very high prevalence country wide, the study is of capital importance.

Materials and Methods {#s1}
=====================

Sample Collection
-----------------

Clinical samples belonging to five experimental groups were included in this study. Experimental groups are (i) the blood of hospitalized patients, (ii) the urine of hospitalized adult patients, (iii) the urine of hospitalized pediatric patients, (iv) the urine of adult outpatients, and (v) the urine of pediatric outpatients. All samples are collected from the patients attending a 1300-bed tertiary hospital in Kayseri, Turkey, between 2014 and 2016. The samples did not include descriptive information from any patients. Identification of *E. coli* strains was performed using conventional microbiological methods and VITEK-2 (bioMérieux) automated system. Extraction of chromosomal DNA was done by growing a single colony of the isolates in Luria--Bertani (LB) broth overnight, collecting pellet in 100 ml sterile Milli-Q water, and boiling at 95°C for 15 min. *E. coli* strains were subjected to confirmatory tests using PCR amplification of the universal stress protein (*uspA*) gene as previously described by [@B9].

Typing of Isolates
------------------

### Phene Plate (PhP) Fingerprinting

All strains were typed using a high-resolution biochemical fingerprinting method specifically developed for *E. coli* strains (PhPlate AB, Stockholm, Sweden; [@B27]). Inoculation of the plates was done according to the manual instruction and the plates were incubated at 37°C. The rate of each reaction was evaluated by measuring the absorbance value in each well after 7, 24, and 48 h of incubation using a digital scanner. After the final scan, the PhPlate software was used to create absorbance (A620) data from the scanned plate images and the mean absorbance in each well over the three readings was calculated, yielding the biochemical fingerprint for each isolate. The biochemical fingerprints of the isolates were compared pairwise and the similarities among the isolates were calculated by the correlation (similarity) coefficient and clustered according to the unweighted pair group method with arithmetic averages ([@B41]; [@B39]). Isolate pairs having a similarity coefficient above the default identity level (0.975) of software was regarded as identical and assigned to the same biochemical phenotype. All data handling, including calculations of correlations and coefficients as well as clustering were performed using the PhPlate software version 4002 (PhPlate AB, Stockholm, Sweden).

### Phylogenetic Grouping

Phylogenetic grouping (A, B1, B2, D) was done for ESBL-EC strains using multiplex PCR with primers coding for *chuA* and *yjaA* genes and the DNA fragment TSPE4.C2 according to [@B10].

Strains belonging to the same biochemical phenotype and phylogenetic groups were considered as members of the same clone and were regarded as common types, and those differing by one method were regarded as single types.

Phenotypic ESBL Detection and Antimicrobial Resistance Test
-----------------------------------------------------------

ESBL production of the isolates was screened by the double-disk synergy on Mueller-Hinton agar using cefotaxime, ceftazidime, cefpodoxime, and ceftriaxone with and without clavulanic acid (10 mg), according to Clinical and Laboratory Standards Institute (CLSI), recommendations ([@B11]). After phenotypic confirmation, the susceptibility of ESBL-EC producing strains was tested against nine antimicrobial agents using Kirby--Bauer disk diffusion methods according to CLSI guidelines. Antimicrobial agents included were ampicillin/sulbactam, ciprofloxacin, gentamicin, sulfamethoxazole, amoxicillin/clavulanate, piperacillin/tazobactam, amikacin, cefepime, imipenem, and ertapenem. *E. coli* ATCC 25922 and ESBL-positive *bla~ctx-m-15~* ESBL-producing strains were used as quality control strains.

*In vitro* Susceptibilities of Bacteriophage Cocktails
------------------------------------------------------

Among all ESBL-EC, one representative from each PhP-common type and all single types are included in phage assay. Spot tests were performed to determine the activities of four commercially available bacteriophage cocktails on each non-replicating ESBL-EC isolate. The bacteriophage cocktails produced in the George Eliava Institute and they were commercially available in sterile media containing 1 × 10^5-6^ phage particles in 1 mL for Pyo-bacteriophage and Intesti-bacteriophage in Georgia. For the remaining two cocktails, the plaque forming unit/mL concentration is not available.

For spot test, all ESBL-EC isolates were initially tested for their purity on MacConkey agar no. 3. One single colony were transferred onto LB agar and incubated at 37° for 18 h. These steps were repeated twice to yield desired colonies (i.e., round shaped) with similar morphology in the agar plates. Single colonies were picked and incubated in LB broth for about 3 h. Then, 100 μL of the bacterial culture (A600 ca. 0.5) mixed with 5 ml of the molten semi-solid LB agar (0.6%) and over laid on the surface of the LB agar. After 10 min, 10 μL of phage suspension was applied on the bacterial layer and incubated at 37°C overnight. Bacterial sensitivity to phage preparations was established by lysis at the spot where the phage was deposited ([@B15]). Observing confluent, semi-confluent, opaque lysis or individual plaques determined the isolate susceptibility. When the lysis was not possible, the corresponding isolates were determined to be resistant. Each test was repeated thrice.

The following four commercial phage cocktails were included in this study.

Enko-phage active against *Salmonella typhimurium*, *Salmonella enteritidis*, *Salmonella heidelberg*, *Salmonella newport*, *Salmonella cholerae*, *Salmonella oranienburg*, *Salmonella dublin*, and *Salmonella anatum*; Shigella flexneri (serovars 1, 2, 3, 4) and Shigella sonnei (six different serovars), enteropathogenic E. coli, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Staphylococcus saprophyticus*.

SES-bacteriophage active against Staphylococci (*S. aureus*, *S. epidermidis*, and *S. saprophyticus*); Streptococci (*Streptococcus pyogenes*, *Streptococcus sanguis*, *Streptococcus salivarius*, and *Streptococcus agalactiae*) and different serotypes of enteropathogenic *E. coli* serovars.

Pyo-bacteriophage active against *Staphylococcus* spp., *Streptococcus* spp, *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Proteus vulgaris*, and *E. coli*.

Intesti-bacteriophage active against *Shigella* spp., *Salmonella* spp., *E. coli*, *Staphylococcus* spp., *Enterococcus* spp., *Proteus* spp., *P. aeruginosa*.

Results
=======

A total of 615 *E. coli* were isolated from urine (*n* = 433) and blood (*n* = 182) cultures of patients (one isolate per patient) included in each experimental group (**Table [1](#T1){ref-type="table"}**). One hundred and seventy-five out of 615 *E. coli* strains were confirmed to be genuine ESBL producers. All 175 ESBL-EC isolates were grouped into 20 common types (i.e., types with more than two identical isolates) and 122 single types based on typing methods. The lowest number of identical isolates in a common type was 2, and the highest number of identical isolates belonging to a common type was 5. With the consideration of clonality the number of representative isolates was determined to be 142 for ESBL-EC. Phylogenetic distribution of these 142 strains revealed that, 40.8% of the isolates belonged to group D, 38.1% belonged to B2, 14.2% belonged to group A, and 7% belonged to B1.

###### 

Numbers of confirmed *E. coli* strains included in this study within each experimental group.

  Experimental groups               Number of *E. coli* strains         
  --------------------------------- ----------------------------- ----- -----
  **Urine**                                                             
  Hospitalized adults               74                            43    117
  Hospitalized children             26                            19    45
  Adult outpatients                 92                            26    118
  Children outpatients              131                           22    153
  **Blood (adults and children)**   117                           65    182
  **Total**                         440                           175   615

ESBL -ve, strains not producing extended-spectrum beta-lactamases; ESBL +ve, strains producing extended-spectrum beta-lactamases.

The rates of ESBL-EC within each experimental group were found to be ranging between 14.7% (for urine culture of children outpatients) and 40.4% (for blood culture of hospitalized patients) (**Table [2](#T2){ref-type="table"}**). In addition to ESBL production all isolates were found to be multidrug resistant (MDR, resistant to \>3 classes; [@B28]; **Table [3](#T3){ref-type="table"}**). The rate of Carbapenem non-susceptible (non-S) strains was found to be ranging between 2.2 and 5.1% among different experimental groups of ESBL-EC.

###### 

Distribution of 615 *E. coli* strains within each experimental group after PhP-typing.

                          Number of representative strains   PhP-types                                 
  ----------------------- ---------------------------------- ----------- ----- ------- --------- ----- -------
  **Urine**                                                                                            
  Hospitalized adults     65                                 33          98    33.7    12 (31)   86    0.996
  Hospitalized children   23                                 14          37    37.9    5 (13)    32    0.991
  Adult outpatients       70                                 21          91    23.01   18 (45)   73    0.994
  Children outpatients    87                                 15          102   14.07   25 (76)   77    0.990
  **Blood**               87                                 59          146   40.4    23 (59)   123   0.996

ESBL -ve, strains not producing extended-spectrum beta-lactamases; ESBL +ve, strains producing extended-spectrum beta-lactamases; DI, diversity index. The numbers in the bracket indicated how many strains belong to common types.

###### 

Antimicrobial resistance percentages of 142 ESBL-EC strains.

  Experimental groups          Antimicrobial agents tested                                                         
  ---------------------------- ----------------------------- ------ ------ ------ ------ ------ ----- ------ ----- -----
  **Urine (83)**                                                                                                   
  Hospitalized patients (47)   82                            73.3   42.3   74.5   51.2   30     5     100    2.2   2.2
  Outpatients (*n* = 36)       79.2                          60.5   24.4   60.2   47.6   20     0     100    0     0
  **Blood (*n* = 59)**         95                            67.8   48     78     59.5   40.7   3.4   96.6   5.1   3.4

SAM, ampicillin/sulbactam; CIP, ciprofloxacin; GEN, gentamicin; STX, sulfamethoxazole; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; AMK, amikacin; FEP, cefepime; IMI, imipenem; ERT, ertapenem.

∗

Reduce susceptibility.

All 142 non-replicating ESBL-EC were included in the bacteriophage assay. According to phage susceptibility assay 131 (92.3%) of the ESBL-EC strains were determined to be susceptible to at least one phage cocktail. Among those, Enko-phage, Intesti- bacteriophage, and Pyo-bacteriophage preparations were active against greater number of isolates than SES-bacteriophage (87.3, 81.7, 81.7, and 59.2%, respectively). Resistance and sensitivity profiles of these four phage preparations are given in **Table [4](#T4){ref-type="table"}**.

###### 

Sensitivity profiles of tested phage cocktails on 142 ESBL-EC included in this study.

                       Number of ESBL-EC strains             
  -------------------- --------------------------- ---- ---- ----
  Confluent            38                          1    38   35
  Semi-confluent       29                          10   27   20
  Opaque lysis         23                          7    23   27
  Individual plaques   34                          66   28   34
  Resistant            18                          58   26   26

ENKO, Enko-phage; SES, SES-bacteriophage; PYO, Pyo-bacteriophage; INTESTI, Intesti-bacteriophage.

Considering the phage susceptibility distributions of the tested strains with respect to different phylogenetic groups, it was observed that each phylogenetic group shows different phage susceptibility characteristics. While Enko, Pyo, and Intesti phages are dominantly effective on B2 and D phylogenetic groups (7.4% resistance rate for all phage cocktails in B2, 3.4, 5.2, and 8.6% resistance rates for Enko, Pyo, and Intesti, respectively in D), a more even susceptibility response can be observed for A and B1 phylogenetic groups (*p* \< 0.00001, chi-square test). This trend can also be observed for SES cocktail with statistical significance (*p* = 0.000295, chi-square test), yet effectiveness for B2 and D phylogenetic groups seems to be less than the other cocktails (27.7 and 34.4% resistance rates for B2 and D groups, respectively) (**Table [5](#T5){ref-type="table"}**).

###### 

Association between phylogenetic groups and phage resistance among 142 ESBL-EC strains.

                Number of strains   Number of strains in each phylogenetic groups                 
  ------------- ------------------- ----------------------------------------------- ---- ---- --- -----------
  **ENKO**                                                                                        
  Resistant     18                  4                                               2    10   2   \<0.00001
  Susceptible   124                 50                                              56   10   8   
  **SES**                                                                                         
  Resistant     58                  15                                              20   17   6   0.000295
  Susceptible   84                  39                                              38   3    4   
  **PYO**                                                                                         
  Resistant     26                  4                                               3    14   5   \<0.00001
  Susceptible   116                 50                                              55   6    5   
  **INTESTI**                                                                                     
  Resistant     26                  4                                               5    13   5   \<0.00001
  Susceptible   116                 50                                              53   7    5   

ENKO, Enko-phage; SES, SES-bacteriophage; PYO, Pyo-bacteriophage; INTESTI, Intesti-bacteriophage; p values were calculated using chi-square test.

ESBL-EC strains isolated from hospitalized patients were more susceptible to Enko-phage than other phage preparations, whereas outpatients' isolates were more susceptible to Pyo-bacteriophage than the other cocktails. Eleven (7.7%) of the ESBL-EC isolates were found to be resistant to all commercially available bacteriophage cocktails. These 11 ESBL-EC were isolated from blood (*n* = 5), from the urine of hospitalized adults (*n* = 2), from the urine of pediatric outpatients (*n* = 2) and from the urine of adult outpatients (*n* = 2). The susceptibility/non-susceptibility patterns of *E. coli* showed no correlation with their antibiotic resistance patterns.

Discussion
==========

Over the past decade, the prevalence of ESBL-EC has attracted the attention of health authorities due to their increasing rates on a daily basis ([@B32]). Recent studies have shown that the prevalence of ESBL-EC in different countries can be as high as 63%, with the highest rate belonging to *E. coli* isolated from ICU patients in Turkey ([@B20]; [@B28]; [@B30]). Reports indicated that ESBL-EC rates are generally very high in Turkey; however, previous studies generally do not take the clonal relationships of the isolates into account ([@B22]). Although molecular typing methods such as pulsed field gel electrophoresis (PFGE) or multilocus sequence typing (MLST) have been used extensively for determining clonal relationships of the investigated strains, for practical purposes, we employed the PhP-typing method that specifically developed to discriminate *E. coli* strains ([@B25]). This system has been used in several epidemiological studies ([@B1]; [@B7]) and was shown to have similar discriminatory power with the genotypic methods ([@B2]; [@B45]). Thus, the ESBL-EC rates (between 14.7 and 40.4%) reported in this study might be indicating a more accurate estimate for Turkish outpatients and hospitalized patients. However, the ESBL-EC ratio especially for hospitalized patients, are still very high and the required precautions should be taken urgently. In addition to ESBL production, the high antibiotic resistance rates found this study might be attributed to their frequent preference in empirical treatment and the overall antibiotics usage policies. A previous Turkish meta-study highlighted the increase of ciprofloxacin, cefepime, co-trimoxazole resistance and ESBL production during the study period of 1996--2012 ([@B4]). As co-resistance to aminoglycosides and quinolones is developed quickly during the ESBL-EC treatments, carbapenems have been the drugs of choice when an infection is caused by ESBL-EC. In this study carbapenem resistance ratio was found to be between 2.2 and 5.1%. Since the carbapenems are still active against the majority of ESBL-EC, clinicians increasingly prefer carbapenems for empiric or definitive therapy in community-onset and nosocomial infections caused by this pathogen ([@B37]). However, this situation results in a frequent explosion of carbapenems to bacteria, which consequently makes the spreading of carbapenemase-producing bacteria scenario more probable and worrisome.

The treatment difficulties on infections caused by MDR pathogens continue to be a vexing problem. Thus, alternative approaches as the treatment options are in quest. Being one of the most popular approaches employing phages as anti-infective agents was adopted in this study. The results of the study indicate that, a great majority (131/142, 92.3%) of diverse ESBL-EC strains were susceptible to at least one phage cocktail. Furthermore, considering the high diversity among each experimental groups based on typing methods, it might be concluded that phages are effective on a broad range of ESBL-EC clones. This is quite promising especially from the point of infections difficult to treat that are caused by MDR pathogens. In an Irish study conducted by [@B14], 82% of ESBL-EC isolated from patients were found to be susceptible to the same bacteriophage cocktails used in current study. Higher percentage found in our study might be explained by the geographical contact between Georgia and Turkey. Because of the neighboring geographies, residents go back and forth between these two countries resulting in bacterial transfers. Thus, as the producer (The G. Eliava Institute of Bacteriophages, Microbiology and Virology) updates its commercial phages regularly, new phages against new strains disseminated from Turkey (e.g., via patients, food, etc.) might find a room in these bacteriophage cocktails. However, in another study conducted by [@B43] in which they used 29 *E. coli* bacteriophages from the Eliava collection in addition to four commercial phage cocktails on *E. coli* set compromising ESBL negative and positive *E. coli*, the phage susceptibility rate was found to be 92.6%. In the current study, 7.7% ESBL-EC isolates were found to be resistant to all bacteriophage cocktails tested. Since the phage cocktails are originated from Georgian biogeography, the phages of these strains might not be contained in the cocktail preparations. On the other hand, isolation of bacteriophages, which are able to be effective on these resistant strains from those pathogens' own environment might be possible. With a specified preparation of phage cocktails and/or with the adaptation of bacteriophages ([@B43]), even more successful susceptibility results are potentially achievable. In our study, SES-bacteriophage was the least active (59.2%) cocktail whereas in [@B14] study, SES-bacteriophage was the most active phage preparation. This outcome might be the indication of different *E. coli* sub-groups being common in Ireland and in Turkey. According to our study, bacteriophage cocktails were found to be effective against all antimicrobial resistance types tested, including carbapenem resistance. This orthogonality between the phage activity and the antimicrobial resistance might be an encouraging factor for the adoption of phage therapy as an alternative or complementary option to difficult to treat infections. For instance, in this study the majority of ESBL-EC (58.4%) were isolated from the urine cultures of the patients. For these patients, carbapenems are generally considered as the drug of choice ([@B35]) and in Turkey there are no oral options for carbapenem treatment. Therefore, treatment for the urinary tract infections caused by ESBL-EC generally requires hospitalization due to intravenous antibiotic therapy application. This is an unfavorable situation as it increases the odds of the patients' being exposed to nosocomial infections, as well as increasing the medical expenses. Considering these multiple drug resistant pathogens are frequently susceptible to the tested phages according to our *in vitro* experiments, employing phage therapy (oral) with *in vitro* tested phage preparations could be an alternative or complementary approach for the cases that narrow spectrum antibiotic therapy is not sufficient or hospitalization is required.

The association of the phylogenetic groups with the virulence characteristics of *E. coli* has been repeatedly reported in the literature, which allows a separation of commensal (A and B1) and pathogenic (B2 and D) strains ([@B5]; [@B13]). As B2 and D are mainly accepted to contain the pathogenic strains, while A and B1 phylogenetic groups are known to mostly include environmental/commensal strains, the altering characteristics might reveal a feature for the employed phage cocktails. According to our results, the cocktails have a particular effectiveness on the pathogenic strains. The underlying reason for that phenomenon might be an artificial selection of "pathogen killing" bacteriophages during phage adaptation procedures since they are selected on clinical strains. Anyhow, this finding can lead us to draw a conclusion that the bacteriophage cocktails are highly specific to selected pathogens, which might turn out to be a preferable feature as they are less likely to harm beneficial components of human microbiome even when they are used orally.

Journals published since 1920s have indicated that the success rate of the *in vivo* phage therapy---orally, rectally, locally, intrapleural injections or intravenously, etc.---is nearly 95%, clinical improvements or full recovery is usually observed within at most 7 days with no reports of serious complications or side effects (allergy, kidney or liver failure, etc.) associated with their use ([@B8]). Although clinical practice of phage therapy as a common medical practice has not been approved yet, except a few Eastern European countries, some studies conducted in EU have already reached the clinical trial phase ([@B29]; [@B36]; [@B46]; [@B33]). As an example, a study started in 2013 and conducted within European Union PF7 programme with the collaboration of researchers from Belgium, France, and Switzerland, achieved their first phage therapy application of burn wound infections on human patients in July 2015^[1](#fn01){ref-type="fn"}^.

Conclusion
==========

This study demonstrated the *in vitro* activity of bacteriophage preparations that are used as a part of standard clinical practice in the Republic of Georgia, against MDR ESBL-EC isolated from Turkish patients. Although bacteriophage therapy has been a successful part of standard healthcare practice for decades, the non-practicing camp has been skeptical to accept bacteriophages as alternative anti-infectives. However, the need for novel antimicrobial therapies have always been of great importance, yet with the emergence of pan-resistant Gram-negative pathogens recently ([@B3]; [@B16]) it could be argued that the quest has never been that crucial since the beginning of the antibiotic era. Thus, *in vitro* confirmation of their success on a well-characterized isolate collection is reported as an initial action, which is encouraging for their clinical use especially for infections with treatment difficulties. Moreover, the effectiveness of generic phage cocktails which are not specifically produced for strains of concern is an implication that the spectrum of phages is large enough to allow their general use.
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